Reply to comment on "The risk assessment of uveitis after COVID-19 diagnosis by Wu et al. 2024"
J Med Virol
.
2024 May;96(5):e29636.
doi: 10.1002/jmv.29636.
Authors
Alan Y Hsu
1
,
Chun-Ju Lin
1
2
3
,
Ning-Yi Hsia
1
2
3
,
Yu-Hsun Wang
4
,
Jing-Xing Li
4
5
6
,
Huan-Sheng Chen
7
,
James Cheng-Chung Wei
4
8
9
10
11
,
Yi-Yu Tsai
1
2
3
Affiliations
1
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
2
School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
3
Department of Optometry, Asia University, Taichung, Taiwan.
4
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
5
Department of General Medicine, China Medical University Hospital, Taichung, Taiwan.
6
Institute of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.
7
An-Shin Dialysis Center, NephroCare Ltd., Fresenius Medical Care, Taichung, Taiwan.
8
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
9
Department of Allergy, Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan.
10
Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
11
Department of Nursing, Chung Shan Medical University, Taichung, Taiwan.
PMID:
38659371
DOI:
10.1002/jmv.29636
No abstract available
Publication types
Letter
MeSH terms
COVID-19* / complications
COVID-19* / diagnosis
Humans
Risk Assessment
SARS-CoV-2 / genetics
Uveitis* / diagnosis
Uveitis* / etiology
Uveitis* / virology